Fig. 4.

A. Anti-Spike (S) IgG (ng/mL) responses raised in sera from participants receiving two doses of LNP-saRNA in the expanded safety cohort by age (18–39 green, 40–59 orange, 60–75 red). Responses are shown on the day of second vaccination, and at 2 and 4 weeks after second vaccination. B. Pseudoneutralising antibodies IC50 from participants receiving two doses of LNP-saRNA responses in the expanded safety cohort by age (18–39 green, 40–59 orange, 60–75 red). Responses are shown 2 and 4 weeks after second vaccination. Error bars detail the median and interquartile range amongst responders. Responses that did not meet criteria for a positive response are shown on the bottom row with numbers of participants <LOQ (limit of quantification).